@article{afa86a2cef8d423aad466d87cb495e23,
title = "May Measurement Month: results of 12 national blood pressure screening programmes between 2017 and 2019",
abstract = "The frst May Measurement Month (MMM) campaign, a global blood pressure (BP) screening programme, began in 2017 as an initiative of the International Society of Hypertension.1 Two subsequent annual campaigns have also been completed in consecutive years2,3 and having had to defer activities due to the COVID-19 pandemic in 2020 the fourth campaign was run in 2021, the results of which are currently in press. Since its initiation in 2017, volunteers from more than 100 countries have participated. The aims of MMM have remained consistent from the start-to raise awareness of the importance of the measurement of BP at the individual and population level and to provide a temporary pragmatic solution to the shortfall in BP screening programmes in countries around the world.",
author = "N.R. Poulter and C. Borghi and A. Damasceno and T.H. Jafar and N.A. Khan and Y. Kokubo and P.M. Nilsson and D. Prabhakaran and M.P. Schlaich and A.E. Schutte and G.S. Stergiou and T. Unger and W. Wang and T. Beaney",
note = "Funding Information: Conflict of interest: N.R.P. has received financial support from several pharmaceutical companies which manufacture BP-lowering agents, for consultancy fees (Servier, Aktiia), research projects and staff (Servier, Pfizer), and for arranging and speaking at educational meetings (AstraZeneca, Lri Therapharma, Napi, Servier, Sanofi, Eva Pharma, Pfizer, Emcure India, Dr Reddy{\textquoteright}s Laboratories). He holds no stocks and shares in any such companies. He is the Chairman of the Steering Committee of the TIME trial. C.B., A.D., T.H.J., N.A.K., Y.K., D.P., W.W., T.B. have no conflicts of interest to declare. M.P.S. has received consulting fees, and/or travel and research support (Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer-Ingelheim). G.S.S. received consulting and lecture fees (Servier and OMRON). T.U. has received honoraria for lectures and advice during the last 3 years (Boehringer-Ingelheim, ICI, Synlab, Vifor, Cipla-India, and Abbott). A.E.S. received speaker honoraria and/or travel support from Omron, Servier, Takeda, Sanofi, Sun pharmaceuticals, and Abbott. P.M.N. received lecturing fees from Novartis, Novo Nordisk, Boehringer-Ingeheim, and Amgen during recent years. He is a member of a regional advisory group for Sanofi. C.B. has received consulting and/or speaker{\textquoteright}s fees (Novartis, Servier, Novo Nordisk, Menarini, Alfasigma). Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.",
year = "2022",
month = oct,
day = "7",
doi = "10.1093/eurheartjsupp/suac045",
language = "English",
volume = "24",
pages = "F1--F5",
journal = "European Heart Journal Supplements",
issn = "1520-765X",
publisher = "Oxford University Press",
number = "SUPP F",
}